<DOC>
	<DOCNO>NCT00048399</DOCNO>
	<brief_summary>To assess safety , feasibility , rate donor engraftment patient primary secondary engraftment failure treatment fludarabine CAMPATH 1H use preparative regimen HLA-identical sibling blood stem cell transplantation ( SCT ) . To assess safety , feasibility , rate donor engraftment patient primary secondary engraftment failure treatment fludarabine CAMPATH 1H preparative regimen match unrelated single antigen mismatch family donor marrow transplantation .</brief_summary>
	<brief_title>Stem Cell Transplantation Patients With Graft Failure Following Allogeneic Transplant , Using Identical Near Identical Donors Less Toxic Conditioning With CAMPATH 1H</brief_title>
	<detailed_description>Study participant receive follow treatment : Day -5 -2 ... Fludarabine 30mg/m2* CAMPATH** 1H 10mg IV Day -1 ... ... ... Day rest Day 0 ... ... ... .Stem cell transplant ( infusion ) Where possible , patient receive peripheral blood stem cell . When peripheral stem cell unavailable ( e.g . unrelated donor center ) insufficient , bone marrow substitute . If peripheral blood stem cell collection perform , donor stimulate G-CSF 5 day cell collect frozen stem cell target number obtain prior patient begin therapy . If bone marrow harvest perform , perform Day 0 ( infusion day ) . After transplantation , G-CSF 5 micrograms/kg/day administer SC day 7 granulocyte &gt; 1000/ul . Because CAMPATH-1H infusion provide persist level antibody transplant period , contribute anti-GvHD activity . Additional GVHD prophylaxis consist FK506 administer IV via continuous infusion 24 hour Day-2 engraftment patient able take mouth , every 12 hour . This continue 6 month post-transplantation . The dose taper every 2 week discontinue . All patient receive supportive care ( prophylaxis antimicrobial , antiviral , antifungal Pneumocystis Pneumonia , transfusion blood product intravenous gamma globulin routine laboratory test chemistry complete blood count ) per Cell Gene Therapy Standard Operating Procedures ( SOP ) . Donor engraftment evaluate via standard bone marrow study ( cytogenetics/DNA study chimerism ) day 30 , 60 , 100 , 180 365 post transplantation . If study reveal loss donor cell two consecutive study and/or evidence relapse disease , donor undergo peripheral blood stem cell harvest via G-CSF stimulation .</detailed_description>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>INCLUSION CRITERIA Diagnosis engraftment failure either primary secondary , follow allogeneic transplantation . Graft failure define absolute neutrophil count &lt; 500/mm3 and/or platelet count &lt; 20,000/mm3 . Primary graft failure define failure maintain absolute neutrophil count &gt; / = 500/mm3 3 consecutive day follow allogeneic transplantation . Secondary graft failure define failure sustain absolute neutrophil count &gt; / = 500/mm3 attainment primary engraftment failure sustain platelet count &gt; / = 20,000/mm3 despite neutrophil engraftment . For SCID patient , graft failure define failure recover &gt; / = 500/mm3 Tcells and/or failure generate satisfactory response vitro mitogen stimulation . For patient genetic disease , engraftment failure define donor chimerism insufficient correct overcome genetic metabolic deficiency . Available Healthy Donor without contraindication donation ( 5/6 6/6 relate donor 5/6 6/6 unrelated donor ( molecular type DRB1 ) Age birth 65 For woman childbearing potential , negative pregnancy test EXCLUSION CRITERIA Pregnant lactate woman woman unwilling use contraception . Uncontrolled intercurrent infection Refractory AML ALL Untreated Blast Crisis CML Uncontrolled Highgrade lymphoproliferative disease/lymphoma Unstable angina uncompensated congestive heart failure ( Zubrod 3 great ) Severe chronic pulmonary disease require oxygen ( Zubrod 3 great ) Hemodialysis dependent Active Hepatitis cirrhosis total bilirubin , SGOT , SGPT great 3 x normal . Concurrent solid organ malignancy remission , except Stage 0 A prostate cancer . Unstable Cerebral vascular disease recent hemorrhagic stroke ( le 6 month ) Active CNS disease hematological disorder .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>